Novo Integrated Sciences, Inc.
Novo Integrated Sciences, Inc. (NVOS) Financial Performance & Income Statement Overview
Explore the financials of Novo Integrated Sciences, Inc. (NVOS), including yearly and quarterly data on income, cash flow, and balance sheets.
Novo Integrated Sciences, Inc. (NVOS) Income Statement & Financial Overview
Analyze Novo Integrated Sciences, Inc.’s NVOS earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $3.15M | $3.17M | $3.89M | $3.30M |
| Cost of Revenue | $2.25M | $1.85M | $1.95M | $2.38M |
| Gross Profit | $896893.00 | $1.32M | $1.94M | $928185.00 |
| Gross Profit Ratio | $0.28 | $0.42 | $0.50 | $0.28 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $3.42M | $2.86M | $5.26M | $4.02M |
| Operating Expenses | $3.42M | $2.86M | $5.26M | $4.02M |
| Total Costs & Expenses | $5.67M | $4.71M | $7.21M | $6.40M |
| Interest Income | $2214.00 | $2477.00 | $2219.00 | $2265.00 |
| Interest Expense | $3.08M | $1.25M | $1.22M | $490273.00 |
| Depreciation & Amortization | $556704.00 | $568209.00 | $572404.00 | $584366.00 |
| EBITDA | -$10.10M | -$924093.00 | -$2.87M | -$2.13M |
| EBITDA Ratio | -$3.20 | -$0.29 | -$0.74 | -$0.58 |
| Operating Income | -$2.52M | -$1.54M | -$3.32M | -$3.09M |
| Operating Income Ratio | -$0.80 | -$0.49 | -$0.85 | -$0.94 |
| Other Income/Expenses (Net) | -$11.22M | -$1.21M | -$1.34M | -$108277.00 |
| Income Before Tax | -$13.74M | -$2.75M | -$4.66M | -$3.20M |
| Income Before Tax Ratio | -$4.36 | -$0.87 | -$1.20 | -$0.97 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $1.06M |
| Net Income | -$13.74M | -$2.75M | -$4.68M | -$3.16M |
| Net Income Ratio | -$4.36 | -$0.87 | -$1.20 | -$0.96 |
| EPS | -$0.74 | -$0.16 | -$0.28 | -$0.20 |
| Diluted EPS | -$0.74 | -$0.16 | -$0.28 | -$0.20 |
| Weighted Avg Shares Outstanding | $18.69M | $17.64M | $16.73M | $15.76M |
| Weighted Avg Shares Outstanding (Diluted) | $18.69M | $17.64M | $16.73M | $15.76M |
Over the past four quarters, Novo Integrated Sciences, Inc. demonstrated steady revenue growth, increasing from $3.30M in Q4 2023 to $3.15M in Q3 2024. Operating income reached -$2.52M in Q3 2024, maintaining a consistent -80% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$10.10M, reflecting operational efficiency. Net income dropped to -$13.74M, with EPS at -$0.74. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan